These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8573812)

  • 1. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A protamine filter for extracorporeal blood heparin removal.
    Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC
    ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy.
    Yang VC; Teng CL; Kim JS
    Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation.
    Yang VC; Port FK; Kim JS; Teng CL; Till GO; Wakefield TW
    Anesthesiology; 1991 Aug; 75(2):288-97. PubMed ID: 1859016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protamine-coated Cuprophan. A potential nonthrombogenic hemodialysis membrane with improved blood compatibility.
    Yang VC; Fu YY; Kim JS
    ASAIO Trans; 1991; 37(3):M229-32. PubMed ID: 1751122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach to anticoagulation control.
    Kim JS; Vincent C; Teng CL; Wakefield TW; Yang VC
    ASAIO Trans; 1989; 35(3):644-6. PubMed ID: 2597555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling.
    Byun Y; Wang T; Kim JS; Yang VC
    ASAIO J; 1996; 42(5):M782-7. PubMed ID: 8944989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation patterns during deheparinization with immobilized polycation.
    von Segesser LK; Mihailevic T; Tönz M; Leskosek B; von Felten A; Turina M
    ASAIO J; 1994; 40(3):M565-9. PubMed ID: 8555578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can protamine be used during perfusion with heparin surface coated equipment?
    von Segesser LK; Gyurech DD; Schilling JJ; Marquardt K; Turina MI
    ASAIO J; 1993; 39(3):M190-4. PubMed ID: 8268526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
    Kirschfink M; Kovacs B; Mottaghy K
    Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal.
    Zhang Y; Singh VK; Yang VC
    ASAIO J; 1998; 44(5):M368-73. PubMed ID: 9804453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR; Johnson S; Brynes R; Monroe S; Guffin AV
    Anesth Analg; 1986 Apr; 65(4):377-80. PubMed ID: 3954111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly-L-lysine amplification of protamine immobilization and heparin adsorption.
    Zhang Y; Singh VK; Yang VC
    J Biomed Mater Res; 1998 Nov; 42(2):182-7. PubMed ID: 9773814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
    Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
    Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
    Chang LC; Lee HF; Chung MJ; Yang VC
    Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigation of coagulation by removing clotting factors part 2: heparin-free extracorporeal circulation in a porcine model.
    Sukavaneshvar S; Parker JT; Beutler DS; Burns G; Solen KA; Mohammad SF
    ASAIO J; 2007; 53(4):421-7. PubMed ID: 17667225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.